Buchumschlag

The effectiveness of 13-valent pneumococcal vaccine against community acquired pneumonia in young children: a systematic review and meta-analysis

Objective. The present meta-analysis study aimed to evaluate the effectiveness of 13-valent pneumococcal conjugate vaccine (PCV) in reducing the morbidity from pneumonia among children under 5 years old. Material and methods. Cochrane and Medline electronic databases were systematically searched for...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Ninel Revenco (VerfasserIn), Ana-Mihaela Balanuta (VerfasserIn), Dina Bujor (VerfasserIn), Adela Horodisteanu-Banuh (VerfasserIn), Olga Cirstea (VerfasserIn)
Format:	Buch
Veröffentlicht:	Amaltea Medical Publishing House, 2022-09-01T00:00:00Z.
Schlagworte:	article
Online-Zugang:	Connect to this object online.
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Effectiveness of 13-valent pneumococcal polysaccharide conjugate vaccine on community-acquired pneumonia: a retrospective cohort study among young children in Suzhou city
von: Zhao-jin LI, et al.
Veröffentlicht: (2022)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
von: V. K. Tatochenko, et al.
Veröffentlicht: (2012)

Distribution of 13-Valent pneumococcal conjugate vaccine serotype streptococcus pneumoniae in adults 50 Years and Older presenting with community-acquired pneumonia in Israel
von: Gili Regev-Yochay, et al.
Veröffentlicht: (2018)

Impact of the pneumococcal 10-valent vaccine on reducing hospitalization for community-acquired pneumonia in children
von: Sandra Rodrigues da Silva, et al.

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
von: S. M. Kharit, et al.
Veröffentlicht: (2016)

13-valent pneumococcal conjugate vaccine in Africa
von: Robert Cohen, et al.
Veröffentlicht: (2017)

Clinical and epidemiological characteristics of severe community-acquired pneumonia in children after introduction of the 10-valent pneumococcal vaccine
von: Lima EJF, et al.
Veröffentlicht: (2015)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
von: James T. Peterson, et al.
Veröffentlicht: (2019)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
von: Johnna Perdrizet, et al.
Veröffentlicht: (2021)

Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children ≤5 years after its implementation into the national immunization program of Turkey
von: Erdem Gönüllü, et al.
Veröffentlicht: (2020)

EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE: EMERGING DATA FROM INVASIVE PNEUMOCOCCAL DISEASE, PNEUMONIA, ACUTE OTITIS MEDIA AND NASOPHARYNGEAL CARRIAGE
von: Ralf Rene Reinert, et al.
Veröffentlicht: (2012)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
von: Thundon Ngamprasertchai, et al.
Veröffentlicht: (2023)

Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
von: Min-Joo Choi, et al.
Veröffentlicht: (2018)

Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
von: Miguel Gouveia, et al.
Veröffentlicht: (2019)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
von: Beate Schmoele-Thoma, et al.
Veröffentlicht: (2019)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
von: Matthew Wasserman, et al.
Veröffentlicht: (2019)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
von: Hye-Young Kim, et al.
Veröffentlicht: (2021)

Direct and indirect effects of 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in children hospitalised with pneumonia from formal and informal settlements in Mongolia: an observational study
von: Jocelyn Chan, et al.
Veröffentlicht: (2021)

Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review
von: Yuanze Du, et al.
Veröffentlicht: (2023)

Evaluation of the impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia in Ulaanbaatar, Mongolia: study protocol for an observational study
von: Claire von Mollendorf, et al.
Veröffentlicht: (2021)

Preventive effects of 23-valent pneumococcal polysaccharide vaccine on community-acquired pneumonia hospitalization in older individuals in China: A case-control study
von: Na Liu, et al.
Veröffentlicht: (2024)

Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants"
von: Jorge A. Gómez, et al.
Veröffentlicht: (2022)

Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants
von: Hua Zhou, et al.
Veröffentlicht: (2018)

PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION
von: A. V. Rudakova, et al.
Veröffentlicht: (2014)

Economic burden of acute otitis media, pneumonia, and invasive pneumococcal disease in children in the United States after the introduction of 13-valent pneumococcal conjugate vaccines during 2014-2018
von: Tianyan Hu, et al.
Veröffentlicht: (2023)

Nasopharyngeal pneumococcal carriage in healthy Turkish children after 13-valent conjugated pneumococcal vaccine implementation in the national immunization program
von: Saliha Kanık Yüksek, et al.
Veröffentlicht: (2020)

Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey
von: J. P. Sevilla, et al.
Veröffentlicht: (2020)

Estimation of 13-valent Pneumococcal Conjugate Vaccine Efficiency in Infants within National Immunization Schedule
von: Nikolay I. Briko, et al.
Veröffentlicht: (2019)

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
von: M. V. Fedoseenko, et al.
Veröffentlicht: (2014)

Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
von: John M. McLaughlin, et al.
Veröffentlicht: (2019)

Effectiveness of 13-valent pneumococcal conjugate vaccine against hypoxic pneumonia and hospitalisation in Eastern Highlands Province, Papua New Guinea: An observational cohort study
von: Christopher C Blyth, et al.
Veröffentlicht: (2022)

Streptococcus pneumoniae carriage among healthy and sick pediatric patients before the generalized implementation of the 13-valent pneumococcal vaccine in Morocco from 2010 to 2011
von: Imane Jroundi, et al.
Veröffentlicht: (2017)

Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study
von: Cheryl Cohen, DrPhD, et al.
Veröffentlicht: (2017)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
von: N. L. Chernaya, et al.
Veröffentlicht: (2012)

Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model
von: Chulmin Park, et al.
Veröffentlicht: (2017)

Effectiveness of 7-valent pneumococcal conjugate vaccine against radiologically diagnosed pneumonia in indigenous infants in Australia
von: KF O'Grady, et al.
Veröffentlicht: (2010)

The effectiveness of the 13-valent pneumococcal conjugate vaccine against hypoxic pneumonia in children in Lao People's Democratic Republic: An observational hospital-based test-negative study
von: Rupert Weaver, et al.
Veröffentlicht: (2020)

A case report of parapneumonic pleural effusion caused by Streptococcus pneumoniae serotype 19A in a child immunized with 13-valent conjugate pneumococcal vaccine
von: Idrissa Diawara, et al.
Veröffentlicht: (2017)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
von: George Gourzoulidis, et al.
Veröffentlicht: (2023)

Analysis of 13-valent pneumococcal polysaccharide conjugate vaccine among children born in Hangzhou from 2017 to 2021
von: Xinren Che, et al.
Veröffentlicht: (2023)